Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Nimenrix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Summary

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Nimenrix (Meningococcal groups A, C, Y, W-135 polysaccharide tetanus toxoid conjugate vaccine) is the brand name for GSK’s tetravalent conjugate vaccine sold in the EU to protect children, adolescents, and adults against four serogroups of N. meningitidis (A, C, Y, W-135) that cause invasive meningococcal infections. Approved in the EU 2012, Nimenrix is the first tetravalent conjugate vaccine available in Europe for patients between 12 and 23 months of age.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nimenrix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nimenrix for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nimenrix performance
- Obtain sales forecast for Nimenrix from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 16
3.3 Prognosis 17
4 Disease Management 18
4.1 Meningococcal Immunization Policy 19
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 22
6 Nimenrix 24
6.1 Overview 24
6.2 Efficacy 25
6.3 Safety 26
6.4 SWOT Analysis 26
6.5 Forecast 27
7 Appendix 28
7.1 Bibliography 28
7.2 Abbreviations 30
7.3 Methodology 31
7.4 Forecasting Methodology 31
7.4.1 Vaccine Coverage 32
7.4.2 Vaccine Approval vs. Routine Schedule Inclusion 32
7.4.3 Vaccines Included 33
7.4.4 Key Launch Dates 34
7.4.5 General Pricing Assumptions 35
7.4.6 Individual Vaccine Assumptions 36
7.5 Physicians and Specialists Included in this Study 37
7.6 About the Authors 41
7.6.1 Authors 41
7.6.2 Reviewers 41
7.6.3 Global Head of Healthcare 42
7.7 About GlobalData 43
7.8 Disclaimer 43



List of Tables

Table 1: Symptoms of Meningococcal Disease 16
Table 2: Meningococcal Immunization Recommendation Agencies by Country 20
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 21
Table 4: Leading Vaccines for Meningococcal Disease, 2012 23
Table 5: Product Profile - Nimenrix 25
Table 6: Nimenrix SWOT Analysis, 2012 26
Table 7: Global Sales Forecasts ($m) for Nimenrix, 2012-2022 27
Table 8: Key Launch Dates 34
Table 9: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 40



List of Figures

Figure 1: Membrane Structure of N. meningitidis 13